8-K

   1


                       SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934


 Date of Report (Date of Earliest Event Reported):   June 29, 2001
                                                  ------------------

                          TRANSKARYOTIC THERAPIES, INC.
- --------------------------------------------------------------------------------
             (Exact Name of Registrant as Specified in its Charter)



                                    Delaware
- ---------------- ---------------------------------------------------------------
                 (State or Other Jurisdiction of Incorporation)

           000-21481                                    04-3027191
- ---------------------------------          -------------------------------------
   (Commission File Number)                  (IRS Employer Identification No.)


195 Albany Street, Cambridge, Massachusetts                        02139
- --------------------------------------------------------------------------------
(Address of Principal Executive Offices)                        (Zip Code)


                                 (617) 349-0200
- --------------------------------------------------------------------------------
               Registrant's Telephone Number, Including Area Code


                                 Not Applicable
- --------------------------------------------------------------------------------
          (Former Name or Former Address, if Changed Since Last Report)






   2




Item 5.  OTHER EVENTS.

     On July 2, 2001, Transkaryotic Therapies, Inc. ("TKT") announced the
completion of its follow-on public offering, raising a total of $100,177,500. A
total of 3,515,000 shares were sold at $28.50 per share, including 415,000
shares to cover overallotments. SG Cowen Securities Corporation acted as
underwriter for the common stock offering.

- -----------.

     The full text of TKT's press release issued in connection with the
foregoing matter is filed as Exhibit 99.1 to this Current Report on Form 8-K and
is incorporated herein by reference.

Item 7.  FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.

     (c) Exhibits.

         99.1 Press Release






                                      -2-




   3


                                    SIGNATURE


     Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

Date:  July 2, 2001                     REGISTRANT

                                        TRANSKARYOTIC THERAPIES, INC.


                                        By: /s/ Daniel E. Geffken
                                           -----------------------------------
                                            Daniel E. Geffken
                                            Senior Vice President, Finance and
                                            Chief Financial Officer



                                      -3-


   4


                                  EXHIBIT INDEX

EXHIBIT NUMBER                 DESCRIPTION
- --------------                 -----------

99.1                           Press Release





                                      -4-

EX-99.1

   1

                                                                    EXHIBIT 99.1

CONTACT:
Justine Koenigsberg
Director, Corporate Communications
(617) 349-0271


FOR IMMEDIATE RELEASE

                  TKT COMPLETES $100 MILLION PUBLIC OFFERING OF
                                  COMMON STOCK

Cambridge, MA, July 2, 2001 -- Transkaryotic Therapies, Inc. (Nasdaq: TKTX)
today announced the completion of its follow-on public offering, raising a total
of $100,177,500. A total of 3,515,000 shares were sold at $28.50 per share,
including 415,000 shares to cover overallotments. SG Cowen Securities
Corporation acted as underwriter for the common stock offering.

A registration statement relating to these securities has been filed with and
declared effective by the Securities and Exchange Commission. Copies of the
prospectus relating to this offering of common stock may be obtained from the
underwriters at the Prospectus Department of SG Cowen Securities Corporation,
One Financial Square, 27th Floor, New York, NY 10005, Attention: Morrin Bass.

Transkaryotic Therapies, Inc. (TKT) is a biopharmaceutical company dedicated to
the development and commercialization of products based on its three proprietary
development platforms: Niche Protein(TM) products, Gene-Activated(R) proteins,
and Gene Therapy. The Company's Niche Protein product platform is based on
protein replacement for the treatment of rare genetic diseases, a group of
disorders characterized by the absence of certain metabolic enzymes. TKT's gene
activation technology is a proprietary approach to the large-scale production of
therapeutic proteins, which does not require the cloning of genes and their
subsequent insertion into non-human cell lines. The Company's Gene Therapy
technology, known as Transkaryotic Therapy(TM), is focused on the
commercialization of non-viral, ex vivo gene therapy products for the long-term
treatment of chronic protein deficiency states.

Gene-Activated(R) is a registered trademark and Niche Protein(TM), TKT(TM), and
Transkaryotic Therapy(TM) are trademarks of Transkaryotic Therapies, Inc.



                                      ###



                                      -5-